Skip to content

Study · Animal study (in vivo) · rhesus monkey · 2014

4 results

[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].

Goncharova ND, Ivanova LG, Oganian TÉ, Vengerin AA, Khavinson VKh

Advances in gerontology = Uspekhi gerontologii1 Jan 2014

PMID25946840 (opens in a new tab)PepBankPUB-25946840

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In old female rhesus monkeys, Pancragen markedly increased glucose disappearance rate after glucose administration compared with the control period.

    In plain wordsIn rhesus monkeys, Pancragen increased glucose disappearance after glucose administration in old females compared with the control period.

    Outcome
    IncreaseGlucose disappearance rate
    Study

    rhesus monkeyn: not reported in source

    old female rhesus monkeys
    Comparator
    control period
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 μg/animal per day · intramuscularly · 10 daysAs given in this study (rhesus monkey).

    Source sentences

    Summary
    Pancragen administration (50 μg/animal per day during 10 days, intramuscularly) to old monkeys caused markedly increased the glucose "disappear- ance" rate,
    2 context sentences
    Summary · context
    In old animals after the glucose administration (standard dose) in control period, a reduced glucose "disappearance" rate and a higher values of insulin and C-peptide peaks (5 and 15 min after the glucose injection) were observed in comparison with young animals in similar experiments.
    Summary · context
    The purpose of this research was to study impact of Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys, and to elucidate the possibil- ity of its use for correction age-related dysfunction of pancreatic islet apparatus.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In old female rhesus monkeys, Pancragen normalized plasma insulin dynamics after glucose administration compared with the control period.

    In plain wordsIn rhesus monkeys, Pancragen normalized insulin responses to glucose in old females compared with the control period.

    Outcome
    Direction not reportedPlasma insulin dynamics
    Study

    rhesus monkeyn: not reported in source

    old female rhesus monkeys
    Comparator
    control period
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 μg/animal per day · intramuscularly · 10 daysAs given in this study (rhesus monkey).

    Source sentences

    Summary
    Pancragen administration (50 μg/animal per day during 10 days, intramuscularly) to old monkeys caused markedly increased the glucose "disappear- ance" rate, normalized the plasma insulin and C-peptide dynamics in response to glucose administration.
    1 context sentence
    Summary · context
    The purpose of this research was to study impact of Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys, and to elucidate the possibil- ity of its use for correction age-related dysfunction of pancreatic islet apparatus.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In old female rhesus monkeys, Pancragen normalized plasma C-peptide dynamics after glucose administration compared with the control period.

    In plain wordsIn rhesus monkeys, Pancragen normalized C-peptide responses to glucose in old females compared with the control period.

    Outcome
    Direction not reportedPlasma C-peptide dynamics
    Study

    rhesus monkeyn: not reported in source

    old female rhesus monkeys
    Comparator
    control period
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 μg/animal per day · intramuscularly · 10 daysAs given in this study (rhesus monkey).

    Source sentences

    Summary
    Pancragen administration (50 μg/animal per day during 10 days, intramuscularly) to old monkeys caused markedly increased the glucose "disappear- ance" rate, normalized the plasma insulin and C-peptide dynamics in response to glucose administration.
    1 context sentence
    Summary · context
    The purpose of this research was to study impact of Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys, and to elucidate the possibil- ity of its use for correction age-related dysfunction of pancreatic islet apparatus.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In old female rhesus monkeys, Pancragen's pancreatic recovery effect partially persisted 3 weeks after discontinuation.

    In plain wordsIn rhesus monkeys, Pancragen's effect on pancreatic function partially remained 3 weeks after treatment stopped.

    Outcome
    Direction not reportedPersistence of pancreatic functional recovery
    Study

    rhesus monkeyn: not reported in source

    old female rhesus monkeys
    Comparator
    control period
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 μg/animal per day · intramuscularly · 10 daysAs given in this study (rhesus monkey).

    Measurements

    Persistence after discontinuation
    3 weeks
    partial pancreatic functional recovery

    Source sentences

    Summary
    The recovering effect of Pancragen on the function of the pancreas partially remained 3 weeks after discontinuation of the drug.
    1 context sentence
    Summary · context
    The purpose of this research was to study impact of Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys, and to elucidate the possibil- ity of its use for correction age-related dysfunction of pancreatic islet apparatus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.